CeleCor Therapeutics is developing Zalunfiban, a next-generation GPIIb/IIIa platelet inhibitor designed for subcutaneous administration in pre-hospital settings for patients experiencing ST-Segment Elevated Myocardial Infarctions (STEMI). This treatment provides rapid platelet inhibition within minutes, addressing the critical issue of high mortality rates from heart attacks occurring before patients reach medical facilities.
Funding
$46.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
A significant percentage of heart attack deaths occur before patients reach the hospital, highlighting the need for immediate intervention in pre-hospital settings. Current treatments lack the rapid action needed to address ST-Segment Elevated Myocardial Infarctions (STEMI) effectively in these critical early moments.
Solution
CeleCor Therapeutics is developing Zalunfiban, an investigational, next-generation GPIIb/IIIa platelet inhibitor designed for subcutaneous administration in pre-hospital settings. Zalunfiban aims to provide rapid, high-grade, and limited-duration platelet inhibition within minutes of administration. Its rapid onset and short half-life are intended to reduce the risk of bleeding and avoid interference with subsequent treatments upon hospital arrival. The drug is currently undergoing a Phase 3 clinical trial to assess its safety and efficacy in improving outcomes for patients experiencing STEMI.
Target Audience
The primary target audience includes patients experiencing STEMI heart attacks in pre-hospital settings, as well as the healthcare providers (e.g., EMTs, paramedics) who administer initial treatment.
Features
- Subcutaneous administration for rapid absorption and ease of use in pre-hospital environments
- Rapid onset of action, achieving maximal effect within 15 minutes
- Limited duration of action with a half-life of approximately two hours
- Designed to provide high-grade platelet inhibition to prevent further clot formation
- Investigational drug being studied in a global, multicenter Phase 3 clinical trial (CeleBrate)